400 filings
Page 11 of 20
6-K
rkdzv4ietefczu1
27 Jun 18
Current report (foreign)
5:27pm
6-K
zkoq52
27 Jun 18
Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018
5:01pm
6-K
fdby2q5v jpq6
12 Jun 18
Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on Atherosclerosis
12:00am
6-K
4iv21alpw8x
8 Jun 18
Current report (foreign)
5:00pm
6-K
uiqeg1
6 Jun 18
Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis
7:00am
6-K
8h59vhdm1na
5 Jun 18
Acasti Pharma Appoints Brian Groch as Chief Commercial Officer
12:00am
D
v00 9sw00t
25 May 18
$837.55K in equity / options / securities to be acquired, sold $372.64K, 1 investor
12:00am
6-K
if2pnw91
18 May 18
Current report (foreign)
8:44am
6-K
i5wgss 807f5a2djv
14 May 18
Acasti Pharma Announces Full Exercise of Over-Allotment Option
2:32pm
6-K
mtye1b 0t4x6
9 May 18
Acasti Pharma Announces Closing of $10 Million Underwritten Offering
5:17pm
6-K
xi9o3qrs
27 Apr 18
Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee
8:00am
6-K
f7j59r
24 Apr 18
Acasti Pharma Prices CDN$10 Million Underwritten Offering in Canada
12:00am
6-K
d7yl1t13b3 qmbf
24 Apr 18
Acasti Pharma Announces Overnight Marketed Canadian Public Unit Offering
12:00am
6-K
hyq9wx qt8b19wlan
2 Apr 18
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
12:00am
EFFECT
qhag3
16 Mar 18
Notice of effectiveness
12:00am
CORRESP
lmzr21v99hbz km2u
15 Mar 18
Correspondence with SEC
12:00am
6-K
5q2qc84taa93hdtwfk3
14 Mar 18
Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program
12:00am
UPLOAD
8kpub6o
12 Mar 18
Letter from SEC
12:00am
F-3
kll fmgy7f
6 Mar 18
Shelf registration (foreign)
12:00am
424B3
2wf1iiqek9 fecc
15 Feb 18
Prospectus supplement
12:00am